Candel Therapeutics Q2 GAAP EPS misses by $0.29

Seeking Alpha··US·Read original
2▲0 ▼1Impact / 5
Summary · why it matters

Candel Therapeutics reported a second-quarter GAAP loss of $0.52 per share, missing analyst expectations by $0.29. The company held cash and cash equivalents of $201.6 million as of June 30, 2026, which it expects will fund operations into the first quarter of 2028. That runway includes activities to support the potential commercial launch of aglatimagene in 2027.

Impact on assets 1

Biotech & Genomic Medicine▼ · 1 stocks
© 2026 MarketIVNews